Layer 1

'No clear evidence that cardiac medicines worsen outcomes of COVID-19'

Tom Cooper is lead cardiology pharmacist at an NHS trust in London
Tom Cooper is lead cardiology pharmacist at an NHS trust in London

A cardiology pharmacist reveals ways for pharmacists to keep abreast of the rapidly changing COVID-19 clinical recommendations

Tom Cooper, lead cardiology pharmacist at Imperial College Healthcare NHS Trust in London, speaks to C+D clinical editor Naimah Callachand in the latest C+D podcast.

When asked about handling patients with COVID-19 who had been taking angiotensin-converting enzyme inhibitors, a question from a listener, he says: “Patients on those medications should be continuing those drugs unless specifically advised to stop.”

COVID-19 is “not a reason to stop” taking cardiac medicines, he says. There is “no clear evidence” that taking the drugs worsen outcomes for these patients, despite discussions about this being a possibility in spring.

The podcast offers a new follow-up interview with Mr Cooper after his appearance on C+D’s webinar at the Clinical Pharmacy Congress on September 24, which explored the range of effects of ‘long COVID’ on patients.

You can listen to the podcast below. Alternatively, subscribe to C+D's podcast on your preferred podcast app by searching “Chemist+Druggist” or on Soundcloud.


Please note, the sound quality of this podcast may be affected as it has been recorded remotely during the COVID-19 outbreak.

Listen to follow-up interviews with two other panellists from the webinar: Oksana Pzyik and Harpreet Chana.

How can pharmacists help patients with long-COVID?
Login or register to post comments

Job of the week

Pharmacist Manager
Midlands, Cheshire & Dorset
Salary dependent upon experience